DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

07 май 2024 15:01:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

01 май 2024 07:00:01 Источник Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

27 фев 2024 07:05:54 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces $500 million Private Placement Equity Financing

27 фев 2024 07:00:37 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

07 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

01 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

08 янв 2024 07:00:01 Источник Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

07 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

30 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

08 авг 2023 15:01:27 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

20 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

08 май 2023 15:01:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

10 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

27 фев 2023 15:01:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

22 фев 2023 15:33:24 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

15 фев 2023 15:01:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

25 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

09 янв 2023 07:00:44 Источник Nasdaq GlobeNewswire

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

05 дек 2022 06:00:41 Источник Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 ноя 2022 15:01:44 Источник Nasdaq GlobeNewswire